Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

5 treatments under study, led by Cisplatin

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1 (1)

Trial Status

Completed1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02140021Not ApplicableTerminated

Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer

NCT02113878Phase 1Completed

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

Showing all 2 trials

Research Network

Common Treatments

  • Cisplatin1
  • Intensitymodulated Radiotherapy Imrt1
  • Buparlisib1
  • Biospecimen Collection1
  • Laboratory Biomarker Analysis1

Active Sponsors

  • National Cancer Institute (NCI)1
  • Novartis Pharmaceuticals1
  • M.D. Anderson Cancer Center1
  • Dana-Farber Cancer Institute1

Top Investigators

Related Conditions

  • Stage Iib Cervical Cancer Ajcc V81
  • Cervical Adenocarcinoma1
  • Stage Ia Cervical Cancer Ajcc V81
  • Vulvar Intraepithelial Neoplasia1
  • Stage Iia1 Cervical Cancer Ajcc V81

Activity Timeline